Semaglutide is in clinical development for the treatment of type 2 diabetes and peripheral arterial disease (PAD). Diabetes mellitus is a condition where blood glucose levels are too high due to an issue with either insulin production (type 1) or insulin resistance (type 2). Over time, people who have diabetes and high blood sugar can develop serious life-threatening diseases, including heart diseases such as PAD. PAD is a common condition where a build-up of fatty deposits in the arteries restricts blood supply to arm or leg muscles. Symptoms often include mild to severe pain in the arms or legs affected. There are not currently any drugs recommended to treat patients with PAD and type 2 diabetes.
Semaglutide for treating peripheral arterial disease (PAD) and type 2 diabetes
Semaglutide is in clinical development for the treatment of type 2 diabetes and peripheral arterial disease (PAD). Diabetes mellitus is a condition where blood glucose levels are too high due to an issue with either insulin production (type 1) or insulin resistance (type 2).